Browse by Medical Category
Accepting New Patients
Dr. Stemmer-Rachamimov is an attending pathologist on the Neuropathology and Autopsy services of Pathology, and is a member of the diagnostic staff of the Cogan Laboratory of Ophthalmic Pathology at Massachusetts Eye and Ear Infirmary.
Go To Programs
Go To Specialties
Anat Stemmer-Rachamimov, MD, is a faculty member of the C. S. Kubik Laboratory for Neuropathology providing diagnostic services, instruction to trainees on the Neuropathology service through didactic teaching sessions and routine sign-out procedures. She is the co-director of the DFHCC Specialized Histopathology Services Core, co-director of the Neuro Oncology Tissue Repository and the director of the Automated Biomarker Laboratory. Her conference activities include weekly or monthly conferences with Pathology, Neurology and Neuro-Oncology. She has particular interest in tumor pathology and the weekly consensus review sessions in which all primary brain tumors are discussed, along with cases of complexity or particular interest. This session allows the neuropathology staff to maintain a consistent set of diagnostic criteria and terminology. She is one of four neuropathologists that diagnose approximately 700 in-house surgical neuropathology cases, and 500 consultation cases per year. In a given year, over 900 intra-operative diagnostic consultations are processed. Her research interests focus on identifying the underlying molecular changes in the lesions and malformations associated with hereditary brain tumor syndromes in particular, neurofibromatosis 1, neurofibromatosis 2, schwannomatosis, and tuberous sclerosis; and comparative pathology with genetically modified mouse models.
Our lab's research focuses on identifying the underlying molecular changes in the lesions and malformations associated with hereditary brain tumor syndromes (neurofibromatosis 1, neurofibromatosis 2, schwannomatosis and tuberous sclerosis), and the identification of activated pathways or events that lead to tumor progression. We are now moving from defining the molecular features and understanding the biology to more practical translational research of biomarkers and drug screens.
See details at the Stemmer-Rachamimov Lab.
View my most recent publications at PubMed
Back to Top